Coherus OncologyvsJohnson & Johnson

CHRS and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

CHRS

Coherus Oncology, Inc.

$0.41

Value $61M

-14.41%
CHRS's page

Coherus Oncology (CHRS) has a market value of $61M and Johnson & Johnson (JNJ) $657B. Over the last year, with dividends, CHRS moved -63.7% and JNJ +39.7%. Dividend yield: CHRS none, JNJ 1.94%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CHRS$61M

    JNJ$657B

    JNJ is 10,696 times CHRS

  • Revenue, 12 months

    CHRS$54M

    JNJ$99.3B

    JNJ is 1,852 times CHRS

  • Net income, 12 months

    CHRS-$136M

    JNJ$16.1B

  • Operating margin

    CHRS-275.9%

    JNJ–

  • ROIC

    CHRS-186.5%

    JNJ12.4%

    198.9 points apart

  • P/E

    CHRS–

    JNJ40.8

  • Dividend yield

    CHRS0.0%

    JNJ1.9%

    1.9 points apart

  • 5-year return

    CHRS-97.8%

    JNJ+92.0%

    189.8 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CHRS-97.8%

JNJ+92.0%

010020020222023202420252026
Returns by period
PeriodCHRSWith dividendsJNJWith dividends
1 year since November 17, 2025-63.7%Price -63.7%+39.7%Price +36.6%
3 years since November 17, 2023-80.8%-42.3% a yearPrice -80.8%+98.2%+25.6% a yearPrice +82.1%
5 years since November 17, 2021-97.8%-53.3% a yearPrice -97.8%+92.0%+13.9% a yearPrice +67.0%
10 years since November 18, 2016-98.5%-34.5% a yearPrice -98.5%+208.0%+11.9% a yearPrice +136.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CHRSCoherus OncologyJNJJohnson & Johnson

Valuation

CHRSJNJ
Valuation
Price$0.41$272.70
Market value$61M$657B
Enterprise value (EV)–$685B
P/E–40.8
P/E, 5-year median–21.9
P/B2.48.1
EV/EBIT–38.6
Free cash flow yield–3.1%

Results and growth

CHRSJNJ
Results and growth
Revenue, 12 months$54M$99.3B
Net income, 12 months-$136M$16.1B
Free cash flow, 12 months-$174M$20.6B
Earnings per share, 12 months-$1.00$6.59
Revenue growth, year on year59.8%6.1%
Revenue growth a year, past-38.4%over 5 years+2.7%over 5 years
EPS growth a year, past-2.5%over 5 years+14.9%over 5 years

Margins and returns on capital

CHRSJNJ
Margins and returns on capital
Gross margin69.8%67.6%
Operating margin-275.9%–
Net margin-253.4%16.2%
ROIC-186.5%12.4%
ROE-216.8%19.7%

Balance sheet

CHRSJNJ
Balance sheet
Cash$84M$17.2B
Total debt–$44.7B
Net debt / EBITDA–1.1
Interest cover-15.5×18.0×

Dividends and buybacks

CHRSJNJ
Dividends and buybacks
Dividend yield–1.9%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CHRS or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Coherus Oncology or Johnson & Johnson?

By market value, Johnson & Johnson ($657B) is about 10,696.3 times Coherus Oncology ($61M), at today's prices.

How did CHRS and JNJ stock do over the last 10 years?

Since November 18, 2016, CHRS's price moved -98.5% and JNJ's +136.4%. With dividends: CHRS -98.5% (-34.5% a year), JNJ +208.0% (+11.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, CHRS or JNJ?

The dividend yield at today's price is none for Coherus Oncology and 1.94% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, Coherus Oncology or Johnson & Johnson?

Over the last twelve months, the net margin was -253.4% for Coherus Oncology and 16.2% for Johnson & Johnson, and the operating margin -275.9% and –. Revenue was $54M and $99.3B.

Which is the better investment, Coherus Oncology or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.